ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ImageneBio IncNASDAQ: IMA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $876K fell 3.1% year over year, ahead of the -67.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1617.6% from the prior quarter. Over 3 fiscal years it compounded at +26.9% a year.

Context

  • Stock-based compensation amounted to 1923.9% of revenue in FY2025, up 1772.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -3.1% holds above the trailing-twelve-month pace of -67.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$876K+1617.6% QoQ
Last fiscal yearDec 2025
$15.39M+190.7% YoY
LTMMar 2026
$1.39M-67.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.1%——
1 year+190.7%——
3-year CAGR+26.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
15.39M USD
Year-over-year change
+190.7%
4-year CAGR
+31.3%

Stock-Based Compensation vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.0% is the 7th highest of 8, against a peer median of -16.6%.
  • Over three fiscal years its annual growth of +26.9% compares with a peer median of +1.9%.
IMA Competitors
Stock-Based Compensation for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$10.03M USD-58.5%-18.9%10.1%
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$6.36M USD-16.6%+1.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$3.73M USD-44.6%+54.6%5821.9%
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
OVIDOvid Therapeutics Inc.LTM Mar 2026$2.41M USD-6.9%-9.8%33.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$1.45M USD+61.5%+10.9%—
IMAImageneBio IncLTM Mar 2026$1.39M USD-67.0%+26.9%—
KLRSKalaris Therapeutics IncLTM Mar 2026$638K USD———
Peer median (excluding IMA) —-16.6%+1.9%768.9%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.12M)(68.77M)(68.17M)(49.23M)(52.4M)
Depreciation & Amortization544K751K1.02M490K328K
Deferred Income Tax00000
Stock-Based Compensation5.18M7.53M05.3M15.39M
Change in Working Capital(33.03M)(15.14M)(21.67M)(3.98M)(19.19M)
Accounts Receivables361K(291K)000
Inventory00000
Accounts Payables00(2.87M)(1.17M)(2.82M)
Other Working Capital(33.39M)(14.85M)(18.8M)(2.81M)(16.37M)
Other Non-Cash Items1.17M1.52M9.07M1.42M8.02M
Operating Cash Flow(60.25M)(74.11M)(79.74M)(46M)(47.84M)
Capital Expenditures(1.76M)(1.43M)(414K)00
Acquisitions (Net)0000(5.22M)
Purchases of Investments0(216.34M)(90.05M)(88.3M)(10.4M)
Sales of Investments0118.49M154.61M60.46M9.8M
Other Investing Activities000(7.07M)0
Investing Cash Flow(1.76M)(99.28M)64.14M(34.9M)(5.81M)
Debt Repayment000015M
Common Stock Issued131.3M037.56M065.84M
Common Stock Repurchased00(663K)00
Dividends Paid00000
Other Financing Activities582K1.1M39.09M054.63M
Financing Cash Flow131.74M1.1M75.98M0135.47M
Effect of Forex Changes00(406K)0604K
Net Change in Cash69.73M(172.3M)59.98M(80.91M)82.41M
Free Cash Flow(62.01M)(75.54M)(80.16M)(46M)(47.84M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.